Genetic and Early-Life Factors Shape the Timing of Multiple Sclerosis Diagnosis
Multiple sclerosis is a chronic inflammatory disease of the central nervous system and a major cause of neurological disability in young adults. Its development is widely understood to arise from a complex interaction between genetic susceptibility, immune dysregulation, environmental exposures, and early-life biological factors. The article by Nova and colleagues advances this field by asking not only which factors increase the likelihood of multiple sclerosis, but also whether these factors influence the timing of diagnosis across the life course. This distinction is scientifically important because a risk factor may exert a stronger effect at younger ages than later in life, a pattern that conventional case–control studies may fail to detect.
A Time-to-Event Approach to Disease Susceptibility
A central methodological contribution of this study is its use of time-to-event analysis rather than a purely retrospective case–control framework. Traditional logistic regression models estimate odds ratios that summarize cumulative disease risk, often assuming that the effect of a risk factor is constant over time. In contrast, the Cox proportional hazards framework used in this study estimates hazard ratios, which describe the instantaneous risk of multiple sclerosis diagnosis at a given age. By following individuals from birth until diagnosis, death, loss to follow-up, or the end of observation, the authors were able to evaluate how genetic and early-life exposures shaped the temporal dynamics of disease emergence.
Study Population and Risk Factors Examined
The analysis was conducted using UK Biobank data and included 345,027 unrelated White participants born in England, among whom 1,669 had a recorded multiple sclerosis diagnosis. The investigators examined a multiple sclerosis polygenic risk score, reflecting inherited genetic susceptibility across the genome, together with early-life and demographic factors such as sex, year and season of birth, number of older siblings, maternal smoking around birth, breastfeeding, multiple birth status, and genetic predisposition to higher body mass index. Smoking and infectious mononucleosis were treated as time-varying exposures, which strengthened the temporal interpretation of the analysis and helped avoid immortal time bias.
Genetic Risk Is Strongest at Younger Ages
One of the most important findings was that the effect of the multiple sclerosis polygenic risk score was not constant across age. Instead, higher genetic risk had a markedly stronger association with multiple sclerosis diagnosis in young adulthood than in later life. For example, the hazard ratio associated with a two-standard-deviation increase in genetic risk was substantially higher at age 20 than at age 60. The visual data presented in the article, particularly the figure on page 5, show a clear decline in genetic hazard ratios with increasing age. This suggests that inherited susceptibility may accelerate the onset of multiple sclerosis rather than simply increasing lifetime probability in a uniform manner.
Sex Differences Also Vary Across the Life Course
The study also identified an age-dependent effect of sex. Females had a higher hazard of multiple sclerosis diagnosis than males, but this difference was most pronounced at younger ages and decreased over time. This finding is consistent with existing biological hypotheses involving sex hormones, immune regulation, sex chromosome effects, and developmental changes around puberty and reproductive age. The age-dependent pattern is particularly relevant because it implies that female sex is not merely a static risk category; rather, its influence on multiple sclerosis susceptibility appears to vary across the life course.
Environmental and Early-Life Contributions
Several non-genetic factors were also associated with multiple sclerosis risk. Smoking on most or all days and previous infectious mononucleosis diagnosis were both linked to increased hazard, supporting the established relevance of tobacco exposure and Epstein–Barr virus-related disease history in multiple sclerosis etiology. A higher body mass index polygenic risk score was also associated with increased hazard, suggesting that genetic predisposition to higher body mass may contribute to disease susceptibility. Season of birth showed an association as well, with individuals born outside autumn demonstrating higher risk, a finding that may relate to prenatal sunlight exposure and maternal vitamin D status. By contrast, breastfeeding, maternal smoking around birth, multiple birth status, and older sibling number were not statistically significant in the main model.
Implications, Limitations, and Future Directions
The study provides a strong argument for applying longitudinal survival models to complex immune-mediated diseases such as multiple sclerosis. Its findings suggest that retrospective designs may underestimate the importance of genetic burden and female sex during younger ages, thereby obscuring clinically meaningful age-dependent risk patterns. Nevertheless, the authors acknowledge important limitations, including the use of diagnosis age as a proxy for disease onset, reliance on recorded diagnoses, limited generalizability beyond White individuals born in England, and possible residual selection bias in UK Biobank. Future research should replicate these findings in more diverse cohorts, incorporate additional early-life biomarkers such as vitamin D levels and Epstein–Barr virus antibody profiles, and explore survival-based genome-wide association approaches to identify genetic variants with age-specific effects on multiple sclerosis risk.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Nova, A., Di Caprio, G., Bernardinelli, L., & Fazia, T. (2024). Genetic and early life factors influence on time-to-multiple sclerosis diagnosis: A UK Biobank study. Multiple Sclerosis Journal, 30(8), 994-1003.
